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Abstract 
As malaria transmission continues to decrease, an increasing number of countries will enter pre-elimination and 
elimination. To interrupt transmission, changes in control strategies are likely to require more accurate identification of 
all carriers of Plasmodium parasites, both symptomatic and asymptomatic, using diagnostic tools that are highly sensi-
tive, high throughput and with fast turnaround times preferably performed in local health service settings. Currently 
available immunochromatographic lateral flow rapid diagnostic tests and field microscopy are unlikely to consistently 
detect infections at parasite densities less than 100 parasites/µL making them insufficiently sensitive for detecting all 
carriers. Molecular diagnostic platforms, such as PCR and LAMP, are currently available in reference laboratories, but 
at a cost both financially and in turnaround time. This review describes the recent progress in developing molecular 
diagnostic tools in terms of their capacity for high throughput and potential for performance in non-reference labora-
tories for malaria elimination.
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Background
Malaria continues to be a significant public health issue, 
with 198 million cases of infection occurring in 2013 [1]. 
However, it is estimated that 55 of the 106 countries that 
reported ongoing transmission in the year 2000 will, by 
2015, meet the target of reducing malaria case incidence 
rates by 75 %. In this context, in 2007, the World Health 
Organization (WHO) endorsed the ambitious goal of 
achieving worldwide malaria elimination and eradication. 
The definitions and associated challenges of elimination 
have been previously discussed [2, 3].
Inherent to a change in focus from control to elimina-
tion is the need to interrupt transmission, which requires 
identification and treatment of all parasite carriers, both 
symptomatic and asymptomatic. To this end, there is 
increasing appreciation of the extent of the asymptomatic 
reservoir of malaria parasites, their potential to maintain 
transmission and the role that sensitive diagnostic tests 
will need to play in providing accurate epidemiological 
information to guide programmatic changes. A review 
by Okell et  al. found that for Plasmodium falciparum, 
microscopy underestimated prevalence by 50.8  % com-
pared with PCR, and that this gap became even more sig-
nificant in low transmission settings [4]. Similarly, Cheng 
et al. described submicroscopic Plasmodium vivax infec-
tion being highly prevalent particularly in areas of low 
transmission, with on average 69.5 % of infections being 
detected only by PCR [5].
The diagnostic tools currently available for the identi-
fication of Plasmodium spp. include light microscopy, 
immunochromatographic lateral flow assays (known 
as rapid diagnostic tests, RDTs), serology, fluorescence 
microscopy and nucleic acid amplification techniques 
(NATs), such as PCR and isothermal amplification. 
Light microscopy has poor sensitivity in low transmis-
sion setting and in asymptomatic patients, resulting in 
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underestimation of disease prevalence compared with 
the gold standard molecular diagnostic tool, PCR [4–6]. 
Even the most sensitive RDTs share similar limitations 
with microscopy [7], and have been shown to be insuf-
ficiently sensitive for community screening of asympto-
matic carriers of P. falciparum [8, 9]. Furthermore, mass 
screening of populations in five malaria ‘hot spots’ in 
Zanzibar and treatment of RDT positive individuals did 
not reduce malaria incidence [9], likely due to the nearly 
tenfold higher undetected and untreated infection reser-
voirs missed by RDTs (compared with PCR). Therefore, 
diagnostic tools with better analytical sensitivity are 
likely to be required to detect the low level parasitaemia 
associated with asymptomatic carriage of Plasmodium 
spp. pertaining to the goal of malaria elimination.
The Malaria Eradication consortium has outlined 
features required of diagnostic tools for the purpose 
of malaria elimination [10]. These were further modi-
fied by the WHO in 2014 [11] to include a lower limit 
of two parasites/µL detected in order to be ‘a significant 
improvement on expert microscopy’. However, the mini-
mum number of parasites per microlitre that perpetu-
ates transmission in low transmission settings remains 
uncertain.
For malaria elimination, the strategies for interrupt-
ing the cycle of transmission rely on enhanced popu-
lation surveillance to inform additional intervention. 
Surveillance for elimination includes reactive and pro-
active active case detection, mass screening/testing and 
treatment (MSAT/MTAT), focused screening and treat-
ment (FSAT) [12] and mass drug administration (MDA) 
[13, 14]. However, the most effective of these strategies 
remains to be determined. While the success of each of 
these strategies will depend on a number of different fac-
tors, the feature common to each of them, except MDA, 
may be the availability of point-of-care, sensitive diagnos-
tic tools that are able to process large numbers of samples 
with a fast turnaround time.
NATs are currently the most sensitive diagnostic 
modality available, and many different assays have been 
developed for the identification of Plasmodium para-
sites. The performance of these assays, in terms of their 
accuracy, has been comprehensively reviewed recently 
[15]. However, while readily available in reference labo-
ratories, NATs such as PCR remains inaccessible in 
resource limited settings due to the expensive infrastruc-
ture, reagents and technical expertise required. Efforts to 
improve the field applicability of NATs have resulted in 
the development of assays such as PCR-enzyme linked 
immunosorbent assays (PCR-ELISA) [16], nucleic acid 
lateral flow immunoassay (NALFIA) [17, 18], nested 
PCR-high resolution melting analysis (nPCR-HRM) [19], 
PCR-ligase detection reaction assays (PCR-LDR) [20] and 
modifications of PCR-LDR into LDR- fluorescent micro-
sphere assay (LDR-FMA) [21]. These assays, which have 
been recently reviewed [22], have good analytical sensi-
tivity but are limited in their field applicability by virtue 
of their requirement for a PCR amplification step.
Isothermal molecular diagnostic modalities, such as 
loop mediated isothermal amplification (LAMP), nucleic 
acid sequence based amplification (NASBA), thermo-
philic helicase dependent amplification (tHDA) and 
recombinase polymerase amplification (RPA), which 
have also been detailed elsewhere [23], are of much cur-
rent interest given their potential to combine good ana-
lytical sensitivity with technical requirements that may 
facilitate application in resource limited settings.
Several NATs, including quantitative PCR (qPCR) 
combined with microfluidics [24], and those linked to 
enzyme-linked immunosorbent assays [25–27] as well as 
non-nucleic acid techniques [28–30] are in development 
for the purposes of malaria diagnosis but are not dis-
cussed further here. However, for even the most promis-
ing molecular technologies to be useful as point of care 
(POC) tests, significant challenges of portability, sample 
preparation, power supply and high throughput [31] have 
yet to be overcome.
This review describes the currently available novel 
molecular diagnostic platforms for the detection of low 
parasitaemia from the point of view of their potential for 
high-throughput and applicability in resource limited 
settings for the purpose of malaria elimination.
Nucleic acid amplification techniques (NATs)
PCR is a very sensitive molecular diagnostic modality 
capable of identifying asymptomatic, submicroscopic 
infection. The sensitivity of PCR for identifying low level 
parasitaemia has been shown to be improved by perform-
ing qPCR using DNA from high blood volumes (up to 
1 ml). The latter platform, as described by Imwong et al., 
has a limit of detection (LOD) of 0.022 parasites/µL [32]. 
This has been achieved using a modified Qiagen© extrac-
tion protocol with extraction of DNA from 1 ml of blood, 
then concentrated to a volume of 10 µL of DNA with 2 µL 
of template per reaction (therefore equivalent to 200 µL 
of blood) in combination with primers to a P. falciparum 
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18S rRNA gene target [32]. The process is amenable to 
up-scaling through automation to test up to 700 sam-
ples per week, confirming its status as a high-throughput 
diagnostic modality. While this technique, when offered 
in a reference laboratory, could make a significant con-
tribution to the detection of low-level parasitaemia, its 
significant drawback is the need for venipuncture, which 
is impractical for population surveillance purposes. In 
addition, the equipment, reagents and technical expertise 
required are likely to preclude its use as a field deploy-
able test. Nevertheless, it highlights the significant diag-
nostic advantages associated with sample concentration 
for identification of low level parasitaemia. The assay has 
been shown capable of identifying most infected individ-
uals in malaria-endemic areas based on the distribution 
of parasite densities in asymptomatic malaria determined 
by this assay [33].
Efforts to simplify PCR for the purpose of field appli-
cation have seen PCR performed directly on blood and 
combined with NALFIA [18] and multiplex malaria sam-
ple ready (MMSR) assays [34]. The MMSR assay relies 
on the lyophilization of all multiplex qPCR reagents in 
either 8-tube strips or 96 well plates which requires only 
the addition of sample DNA and water for the identifica-
tion of Plasmodium genus and P. falciparum at an LOD 
of 0.244 parasites/µL from whole blood. The assay can 
also identify P. vivax. Although MMSR still requires a 
thermocycler, DNA extraction and is expensive (> US$10 
per reaction), it overcomes some significant issues asso-
ciated with performing PCR in resource limited settings, 
thereby providing proof-of-concept for the potential PCR 
has to become deployable in non-reference laboratory 
settings.
To overcome the issue of equipment in field settings, 
Canier et al. created a mobile molecular laboratory [35]. 
At a cost of US$200,000 for the fully equipped truck, this 
laboratory is able to process 240 samples per day, with a 
turnaround time of 24  h and a cost of US$2.75/sample. 
The real time assay was performed in a 96-well plate 
using DNA extracted from filter paper using a commer-
cial kit (Instagene Matrix resin, BioRad). Samples were 
screened for Plasmodium spp. using a mitochondrial 
cytochrome-b target [36] and then a species-specific 
nested real time PCR performed to arrive at an LOD of 
two parasites/µL from a 5 µL dried blood spot (DBS) [35]. 
While this innovative approach provides the opportunity 
for performing field-based PCR with its associated high 
throughput and fast turnaround time, the cost outlay of 
the mobile laboratory and cost per sample may be pro-
hibitive in many developing countries embarking on 
malaria elimination programmes.
A significant advantage of real-time PCR is the lack of 
post-PCR handling through the use of fluorophores. To 
overcome issues of expense, Lucchi et al. [37] developed 
a novel, low cost technique for labelling real-time PCR 
primers with self-quenching ability via photo-induced 
electron transfer (PET). The PET-PCR assay was per-
formed on Qiagen©-extracted DNA using a duplex of 
Plasmodium genus and P. falciparum primers, and was 
found to have an LOD of 3.2 parasites/µL [37]. Validation 
of the assay on nearly 3000 surveillance samples from 
Haiti, took over 5  months to process [38]. Therefore, 
while PET-PCR would appear to offer a sensitive platform 
for performing real time PCR, it is unclear whether the 
overall cost of the technology coupled with turnaround 
time would render it amenable for field deployment for 
malaria elimination.
Portable, self-contained molecular technology is the 
ultimate prize in the development of field applicable 
diagnostic tools. The first of these is based on a plastic 
hydrogel chip and a customized portable real time PCR 
machine (Gelcycler) [39]. The assay can process 12 sam-
ples at a time, directly from whole blood, with no prior 
DNA extraction. The assay uses an 18S rRNA gene tar-
get that detects all species of Plasmodium with an LOD 
of two parasites/µL and differentiated between P. falci-
parum and P. vivax [39]. The assay had a 2 h turnaround 
time using a 12 volt battery and costs US$1 per test and 
US$2000 for the gelcycler [39]. Although able to process 
only 12 samples at a time, the low cost, self contained 
nature of this chip and ability to test blood directly with 
a fast turnaround time make it an enticing prospect for 
field applicable diagnostics. The second platform is a 
multiplex microarray assay, targeting 26 tropical patho-
gen species including P. falciparum and P. vivax, with a 
turnaround time of 4  h [40]. However, its cost and loss 
of sensitivity at less than 100 parasites/µL for P. falcipa-
rum suggest a limited role for the assay for the purpose of 
malaria elimination.
Another approach to increasing sample throughput 
is pooling of samples [41]. In this study by Hsiang et al., 
filter paper samples were pooled into groups of 10, 50 
and 100 and tested by real time PCR and species differ-
entiated using a restriction enzyme analysis. The study 
found that at 10 parasites/µL, a pool of ten had a sensi-
tivity of 93 % for P. falciparum [41] but turnaround time, 
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throughput and cost of this approach are unclear. How-
ever, pooling strategies are only likely to be cost effective 
in areas with very low level transmissions, and where 
parasitaemic subjects have a moderate parasitaemia, 
which may permit pooling of DNA samples, thereby lim-
iting its potential role in elimination settings.
Finally, RNA assays are generally considered too tech-
nically challenging for application in resource limited set-
tings. Nevertheless, Cheng et al. have developed a capture 
and ligation probe PCR (CLIP-PCR) where sample lysate 
are directly incubated with a target plate overnight, obvi-
ating need for RNA purification and reverse transcrip-
tion. qPCR can then be performed and results analysed 
by melting curve analysis and cycle threshold values. It 
is high throughput by virtue of its 96-well plate format 
and sample pooling, and can be performed directly from 
whole blood with an LOD of 0.05 parasites/µL or from 
pooled DBS with an LOD of 0.3 parasites/µL [42]. More 
than 3000 DBS were processed in the study but through-
put per day is unclear. Limitations are an overnight incu-
bation step which extends turnaround time, ability to 
identify only Plasmodium genus and requirement for 
PCR. Nevertheless, the potential for high throughput and 
direct processing from blood opens the possibilities for 
RNA assays to enter the foray of diagnostics for malaria 
elimination.
Loop mediated isothermal amplification (LAMP)
Since its first description in 2001 by Mori et  al. [43], 
LAMP has become a forerunner in isothermal diagnostic 
technology for the identification of Plasmodium species 
[23]. LAMP has been used to identify all human Plasmo-
dium species [44] including Plasmodium knowlesi [45, 
46], and LAMP primers have been optimized to improve 
the sensitivity with which P. falciparum [47, 48] and P. 
vivax [49, 50] can be detected. A commercially available 
Loopamp kit (Eiken Chemical co) has been validated for 
the detection of P. falciparum [51] and enables the indi-
rect detection of P. vivax using a combination of pan-
genus and P. falciparum specific LAMP primers [52]. 
Given that the commercial LAMP turbidimeter has lim-
ited capacity, Loopamp kits have been successfully com-
bined with 46-well heat blocks and UV lamps to increase 
throughput [53, 54]. Nevertheless, further optimization 
of LAMP platforms will be needed in order to viably pro-
cess large numbers of samples as might be required to 
broaden its applicability for malaria elimination [31, 55].
Goto et al. [56] described a simple LAMP platform to 
improve its throughput using a 96-well microtitre plate 
format and a metal ion detector, hydroxynaphthol blue 
(HNB), for rapid visual interpretation of positive and 
negative results. This platform has been adapted for the 
identification of Plasmodium genus and P. falciparum as 
a high-throughput LAMP (HtLAMP) assay that can be 
combined with a portable photospectrometer for objec-
tive confirmation of visually detectable HNB colour 
change results [57]. Its LOD for the identification of Plas-
modium genus (HtLAMP-Pg) is 2.5 parasites/µL from 
whole blood and 25 parasites/µL from DBS. The cost of 
HtLAMP-Pg is US$1 per sample which includes whole 
blood DNA extraction using a modified chelex-saponin 
protocol. Although HtLAMP requires DNA extraction 
and is yet to be validated on asymptomatic patient sam-
ples to confirm throughput capacity, it has been per-
formed in a resource limited setting and offers a cost 
effective molecular diagnostic platform.
Notwithstanding the issue of high-throughput, one of 
the exciting aspects of LAMP has been its potential for 
field deployment by virtue of its isothermal nature, and 
as such efforts have been invested in improving its field 
readiness. Lucchi et al. described the RealAmp platform 
in which LAMP was housed in a portable tube scanner 
with a built-in fluorescent detection unit able to moni-
tor the generation of fluorophores by SYBR green in 
real time rather than reliance on visual colour change 
[58]. The device is a compact, 8 tube well, closed-system 
with an LOD of 0.4–40 parasites/µL for Plasmodium 
genus detection depending on method of DNA extrac-
tion. Costs are quoted at US$6344 start-up and US$2.66 
per sample at minimum. RealAmp has also been used to 
detect P. vivax [49], and has been validated in field testing 
[59].Therefore, while this platform itself appears portable 
and relatively sensitive, its potential role in malaria elimi-
nation may be limited by its throughput and cost.
The concept of lateral flow based immunodiagnostics is 
familiar to the field of malaria. LAMP has been combined 
with a lateral flow device (LFD) thus adapting a molecular 
assay into a rapid diagnostic device [60]. This LAMP-LFD 
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assay, performed on extracted DNA or directly on blood, 
targets the dihydrofolate reductase thymidylate synthase 
(dhfr-ts) genes of P. falciparum and P. vivax using bioty-
nylated LAMP primers whose products then hybridized 
with FITC labelled single strand DNA. A strepavidin-bio-
tin reaction between hybridized LAMP amplicons and 
gold-labelled anti-FITC antibodies on the LFD strip allow 
visualization of the result [60]. However, this LAMP-LFD 
platform has limited sensitivity at low-level parasitaemia, 
and has not been validated on clinical samples. Impor-
tantly, it is a multistep process, requiring the addition of 
the probe at the end of the LAMP reaction, making this 
open system vulnerable to contamination, particularly 
where high throughput sample processing is necessary. 
Nevertheless, the potential for simple visualization of 
results offered by LFD, combined with either LAMP [60], 
recombinase polymerase amplification (RPA) [61] or 
PCR [18], is promising.
Field applicability of diagnostics devices centre around 
simplicity of the assay and ability to be performed with 
minimal instrumentation but generally still depend on 
a reliable electricity supply. Non-instrumented nucleic 
acid amplification (NINA) [62] has been applied to the 
detection of Plasmodium species as a LAMP-NINA assay 
[63]. This assay uses an exothermic chemical reaction 
between saline and a magnesium iron alloy to generate a 
heat source for performing LAMP on a maximum of five 
samples within an insulated thermos flask-like device, 
and was validated in Ethiopia using Loopamp malaria 
pan genus/Pf kits (Eiken chemical co, Japan) in the NINA 
heating device [63]. Its limitations are its lack of capacity 
for high throughput, risk of contamination and validation 
only in samples with relatively high parasitaemia. How-
ever, the self-contained electricity free heating device, 
lack of post processing handling and fast turnaround 
time make it an attractive prospect as a field applicable 
point of care diagnostic device.
Conclusion
The extent of the submicroscopic parasite reservoir is 
becoming more evident with the utilization of sensitive, 
reference laboratory-based PCR testing. Microscopy and 
RDTs have been shown to underestimate the Plasmodium 
parasite prevalence in low incidence settings when com-
pared with PCR, which has important implications for 
malaria elimination [9, 64]. The availability of sensitive 
diagnostic tests would also facilitate improved diagnosis 
of causes of febrile illness as malaria incidence declines 
and allow for more appropriate administration of arte-
misinin combination therapy (ACT) [19]. Although many 
diagnostic platforms may be capable of fulfilling this role, 
given the sensitivity of NATs, there is an increasing prior-
ity for the development of molecular diagnostic tools that 
have the capacity for detection of low level parasitaemia, 
that are able to process large numbers of samples and that 
can be performed in regional, non reference laboratory 
settings in order to support efforts of malaria elimination.
The various novel PCR and LAMP platforms currently 
available (Table  1) have demonstrated variable analyti-
cal sensitivity; many of these have yet to be validated 
among asymptomatic patients for the specific pur-
pose of identifying low-level parasitaemia and have yet 
to be evaluated in resource limited settings. The main 
dichotomy between the two types of molecular assays 
remains that PCR-based assays have the sensitivity of 
parasite detection and the infrastructure support to 
increase throughput of sample processing, but have lim-
ited capacity to be deployable to more resource-limited 
laboratory settings. Isothermal assays, such as LAMP 
on the other hand, appear to have adequate analytical 
sensitivity to detect low-level parasitaemia and strong 
potential for deployment in non-reference laboratory 
settings but have limited, often implied rather than 
proven, capacity for high throughput processing of 
samples. Furthermore, many of these platforms are yet 
to overcome the common hurdle of simplifying nucleic 
acid extraction, an essential requirement for such assay 
platforms in resource limited settings. Both PCR and 
LAMP based assays are currently more expensive than 
RDT. Nevertheless, engineering challenges may be sur-
mountable and strong foundations have been laid for 
achieving the goal of developing sensitive molecular 
diagnostic tools with the capacity for both field deploy-
ment and high throughput sample processing for the 
purpose of detecting low-level parasitaemias in malaria 
elimination settings.
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